CordenPharma

Executive Summary

CordenPharma is a leading global CDMO specializing in complex pharmaceutical manufacturing, including APIs, drug products, and lipid excipients. With deep expertise in peptides, oligonucleotides, and lipid nanoparticles, the company supports the growing demand for advanced therapies. Its integrated network across Europe and North America positions it as a key partner for biopharma innovators. Recent investments in capacity and technology, such as expansion of its peptide manufacturing and LNP capabilities, underscore its commitment to capturing demand in high-growth modalities. The CDMO market is benefiting from continued outsourcing trends and the rise of novel therapeutics. CordenPharma's focus on complex modalities and its global footprint provide a competitive edge. However, challenges include pricing pressure and the need for continuous innovation. Overall, the company is well-positioned for sustained growth, driven by its comprehensive service offering and strategic expansions.

Upcoming Catalysts (preview)

• Q2 2027Completion of peptide manufacturing capacity expansion in Europe80% success
• Q3 2026New long-term agreement with a top-20 pharma for LNP-based drug delivery60% success
• Q4 2026Launch of next-generation oligonucleotide synthesis platform70% success